NCT05091567

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2021-11-18Est. Completion: 2024-07-29

Enrollment target: 660 participants

Locations

Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States
Illinois Cancer Care, Peoria, Illinois, United States
New England Cancer Specialists, Scarborough, Maine, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
Clinical Research Alliance, Westbury, New York, United States
The Mark H. Zangmeister Ctr, Columbus, Ohio, United States
Rhode Island Hospital, Providence, Rhode Island, United States
Hollings Cancer Center, Charleston, South Carolina, United States
Greco-Hainesworth Centers for Research, Chattanooga, Tennessee, United States
West Clinic, Germantown, Tennessee, United States
Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, United States
Institut Jules Bordet, Anderlecht, Belgium
Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium
UZ Leuven Gasthuisberg, Leuven, Belgium
AZ St Maarten Campus Leopoldstr, Mechelen, Belgium

Non Squamous Non Small Cell Lung Cancer

This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity…

Yerevan, ArmeniaEst. completion Aug 31, 2026

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy …

Duarte, United StatesCompleted Mar 9, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.